<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01926821</url>
  </required_header>
  <id_info>
    <org_study_id>SIZO2013</org_study_id>
    <nct_id>NCT01926821</nct_id>
  </id_info>
  <brief_title>Impact of Sonifilan on the Quality of Life in Patients With Cervical Cancer During Radiation or Chemoradiation Therapy</brief_title>
  <official_title>The Impact of Sonifilan on the Quality of Life in Patients With Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The impact of sonifilan on the quality of life in patients with cervical cancer during
      radiation or chemoradiation therapy

        1. Primary endpoint : Quality of life

        2. Secondary endpoint : complications related to Sonifilan, treatment effect of Sonifilan
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design Prospective randomized controlled trial

      Study period Protocol registration approval date - may/31/2016

      Study drug Sonifilan(Sizofiran)

      Study population

        1. Cervical cancer FIGO stage IA2-IVA patients will be participated.

        2. Squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma

        3. age 20-75 year

      Treatment Fron the day of radiation therapy started, Sonifilan 20mg, 1amp IM/week for 8weeks

      Concurrent therapy Chemo &amp; radiation therapy

        1. Cisplatin 40mg/m2, day 1, 8, 15, 2, 29, 36

        2. External whole pelvic irradiation 3000-3500 cGy / 6 fractions in high dose rate

      Assessment

        1. Pre-study assessment (within 4weeks before participation) a medical history b informed
           consent c ID number assignment d life quality assessment - fill out EORTC QOQ-C30, CX24,
           SF-36, FSFI e basic information collect

        2. On-study assessment (during study) a complication check b life quality assessment - fill
           out EORTC QOQ-C30, CX24, SF-36, FSFI

      3. Post-study assessment (1week after study finished) a MRI b PAP smear c HPV test d life
      quality assessment - fill out EORTC QOQ-C30, CX24, SF-36, FSFI

      4 Follow-up assessment (every 3 month for 1 year) a Pelvic exam b PAP smear c HPV test d MRI
      (if needed) e PET (if needed) f life quality assessment - fill out EORTC QOQ-C30, CX24,
      SF-36, FSFI 93, 6, 12, 24 month after study finished)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 year</time_frame>
    <description>life quality assessment by filling out EORTC QOQ-C30, CX24, SF-36, FSFI pre-/on-/post-study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications of drug, treatment effects</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>sonifilan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group who get sonifilan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Sonifilan administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sonifilan</intervention_name>
    <description>Sonifilan inj 20mg Intra muscular injection, twice per week for 8 weeks, total 16 times</description>
    <arm_group_label>sonifilan</arm_group_label>
    <other_name>sizofiran inj 20mg</other_name>
    <other_name>Code : XSISO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cervical cancer FIGO stage IA2 - IVA

          -  Histologic type : SCC, Adenocarcinoma, Adenosquamous carcinoma

          -  GOG performance status 0-2

        Exclusion Criteria:

          -  past radiation therapy history

          -  Neuroendocrine carcinoma

          -  concurrent other cancer

          -  uncontrolled medical disease

          -  ulcerative disease history

          -  current pregnancy and lactation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jongHyeok Kim, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Asan Medical Cneter</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>WooSuk Han, Master</last_name>
    <phone>82-10-4818-9296</phone>
    <email>bronx46@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>JongHyeokKim</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2013</study_first_submitted>
  <study_first_submitted_qc>August 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2013</study_first_posted>
  <last_update_submitted>May 27, 2017</last_update_submitted>
  <last_update_submitted_qc>May 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Jong-Hyeok Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sizofiran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

